AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10024335
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Enalapril + Simvastatin)
Trial: 7571926
Drug: Cerebrolysin injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin injected in retrobulbar space and in combination with trental
Trial: 29906741
Drug: My-GMC (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: My-GMC (Group medical consultations combined with tablet-based online app)
Trial: 27390976
Drug: Bivalirudin IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin IV bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h until the end of the PCI.
Trial: 27390976
Drug: Heparin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (70 UI/kg) intravenous bolus.
Trial: 17583798
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin 7.5 mg daily
Trial: 7733478
Drug: Depogen with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depogen with heparin
Trial: 30075741
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment according to NICE guidelines
Trial: 24193233
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution at 5 mL/kg/h
Trial: 24193233
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution at 5 mL/kg/h and dopamine 3 mg/kg/min
Trial: 24193233
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution at 10 mL/kg/h
Trial: 20233037
Drug: Low-fat, high-complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-complex carbohydrate with 1.24 g high oleic sunflower oil supplement (LFHCC)
Trial: 20233037
Drug: Low-fat, high-complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-complex carbohydrate with 1.24 g long chain n-3 poly-unsaturated fatty acid (LC n-3 PUFA) supplement (LFHCCn-3)
Trial: 12410780
Drug: Clonidine and
RxNorm normalized name: clonidine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine and other symptomatic medications (up to 8 days)
Trial: 7273012
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 3‐4 mg/m2 iv every 10‐14 days
Trial: 7273012
Drug: Continuous 5‐day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 5‐day infusion of 1‐1.2 mg/m2/day every 21 days
Trial: 7273012
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion after failing to respond to bolus vindesine
Trial: 25022119
Drug: Saturated moxa
RxNorm normalized name: Moxatag
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saturated moxa dosage group
Trial: 25022119
Drug: Regular moxa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular moxa dosage group
Trial: 19440837
Drug: Think Smart
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Think Smart curriculum (school-based drug prevention curriculum)
Trial: 17303783
Drug: Allopurinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (600 mg oral dose) before lower arm occlusion
Trial: 17303783
Drug: Allopurinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (600 mg oral dose) before upper arm occlusion
Trial: 15134107
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% xylocaine jelly and 0.5 ml of intracameral 1% lidocaine
Trial: 15134107
Drug: Sub-Tenon infiltration
RxNorm normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Tenon infiltration with 2 ml of 2% xylocaine
Trial: 2190630
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg controlled release (CR) salbutamol tablets twice daily
Trial: 2190630
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg standard salbutamol tablets four times daily
Trial: 677866
Drug: Ticarcillin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin plus gentamicin (T+G)
Trial: 677866
Drug: Cephalothin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin plus gentamicin (C+G)
Trial: 25618318
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) 75-mg tramadol/650-mg acetaminophen after a single dose
Trial: 25618318
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) 37.5-mg tramadol/325-mg acetaminophen after 2 doses
Trial: 25618318
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) formulation with food
Trial: 25618318
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) formulation with food
Trial: 15169807
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg plus carboplatin and paclitaxel
Trial: 9766493
Drug: 9-cis retinoic
RxNorm normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9-cis retinoic acid (RA) at doses ranging from 30 to 230 mg/m2/day
Trial: 2984100
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg sublingually
Trial: 2805362
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg per os bid for 3 months
Trial: 1111464
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prednisone and fluoxymesterone
Trial: 31911341
Drug: Therapy stratified
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy stratified by endotype (intervention group)
Trial: 25981528
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment with customized information and education
Trial: 23864139
Drug: Radon spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radon spa therapy
Trial: 23864139
Drug: Radon spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radon spa therapy in OA patients
Trial: 16554580
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with an investigational drug
Trial: 11375828
Drug: IV injection
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection of 2 g propacetamol every 6 h for 3 days after surgery
Trial: 9404448
Drug: rhGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH therapy (0.25 IU/kg/week sc)
Trial: 12061306
Drug: Chlorhexidine solution
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine solution (1.2%)
Trial: 2907896
Drug: GnRH (gonadotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH (gonadotropin releasing hormone)
Trial: 18294761
Drug: Electrostimulated acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulated acupuncture (EA) weekly for 12 weeks
Trial: 18294761
Drug: Traditional acupuncture
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional acupuncture (TA) weekly for 12 weeks
Trial: 3983422
Drug: Misonidazole (1
RxNorm normalized name: Fluoromisonidazole (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misonidazole (1 g/m2, total 13-14 g/m2) given on every irradiation day
Trial: 3983422
Drug: Radiotherapy (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (3 daily fractions of 1.6 Gy for 2 weeks, total dose 48 Gy, boost to about 70 Gy after 3-4 weeks)
Trial: 31265730
Drug: Azathioprine (IFX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (IFX 0 mg/kg)
Trial: 29754251
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation and counselling intervention delivered by a pharmacist
Trial: 26393904
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (tamsulosin 0.4 mg and tolterodine 4 mg)
Trial: 26393904
Drug: Monotherapy (tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (tamsulosin 0.4 mg and placebo)
Trial: 22315282
Drug: Low-dose BH4
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose BH4 (400 mg/d)
Trial: 22315282
Drug: High-dose BH4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BH4 (700 mg/d)
Trial: 27310958
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 25 μg
Trial: 19897803
Drug: Systemic hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic hydromorphone 1 mg IV and 1 mg IM
Trial: 18569914
Drug: Oral 300,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 300,000 IU cholecalciferol supplementation
Trial: 10695779
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg single dose of oral dihydroartemisinin (DHA)
Trial: 8961361
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 325 mg daily for 1 year
Trial: 1901203
Drug: Lithium-imipramine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium-imipramine combination
Trial: 6349943
Drug: Hydrocortisone valerate
RxNorm normalized name: Hydrocortisone Valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone valerate 0.2 percent ointment
Trial: 16876559
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medical therapy only)
Trial: 31115908
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks (Q2W)
Trial: 30215677
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg Q2W
Trial: 31115908
Drug: Nivolumab 10
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 10 mg/kg Q2W (global population)
Trial: 25091664
Drug: BRV-TV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRV-TV vaccine (10^5.0 FFU)
Trial: 25091664
Drug: BRV-TV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRV-TV vaccine (10^5.8 FFU)
Trial: 25091664
Drug: BRV-TV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRV-TV vaccine (10^6.4 FFU)
Trial: 19717345
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (n=251)
Trial: 11917277
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg) administered before each chemotherapy cycle in the phase II trial and before carboplatin administration in the intensification trial.
Trial: 11917277
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (60 Gy) and carboplatin (700 mg/m² cumulative dose) without amifostine in the control group of the phase II trial.
Trial: 11917277
Drug: Carboplatin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (70 mg/m²) on specific days during radiotherapy in the intensification trial.
Trial: 9814616
Drug: DCLHb 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb 25 mg/kg
Trial: 9814616
Drug: DCLHb 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb 50 mg/kg
Trial: 9814616
Drug: DCLHb 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb 100 mg/kg
Trial: 7503066
Drug: DCLHb (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb (all doses)
Trial: 22448480
Drug: 2-glass test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-glass test before finger rectal test (FRT)
Trial: 9330936
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion (2 ng/kg/min for 8 hours)
Trial: 9330936
Drug: Iloprost (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (9 infusions over 6 months)
Trial: 9330936
Drug: Nifedipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (40 mg/day for 6 months)
Trial: 3519382
Drug: Defibrotide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (200 mg IV four times a day for 7 days)
Trial: 30289950
Drug: Darapladib (Lp‐PLA2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib (Lp‐PLA2 inhibitor)
Trial: 15712536
Drug: Serial lumbar
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial lumbar puncture and acetazolamide combination
Trial: 12540416
Drug: Probiotic fermented
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic fermented milk drink (65 mL with Lactobacillus GG, Bifidobacterium sp B420, Lactobacillus acidophilus 145, and Streptococcus thermophilus; n = 108)
Trial: 12540416
Drug: Standard yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard yogurt (180 g; n = 101)
Trial: 8858355
Drug: BSS Plus
RxNorm normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSS Plus with heparin and dexamethasone (HD)
Trial: 1516609
Drug: Oral alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alprazolam (1 mg)
Trial: 1516609
Drug: Sublingual alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual alprazolam (1 mg)
Trial: 9386146
Drug: Placebo (sublingual)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sublingual)
Trial: 1516609
Drug: Both routes
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both routes of alprazolam (oral and sublingual)
Trial: 20047095
Drug: low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose cytosine arabinoside and aclarubicin (CA)
Trial: 12454227
Drug: Diclofenac infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac infusion
Trial: 31665842
Drug: Five-in-one asthma
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-in-one asthma management model (standardized asthma treatment, asthma diary, PEF monitoring, reasonable diet and physical exercise)
Trial: 31665842
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication and regular outpatient consultation (control group)
Trial: 25420010
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and exercise program aimed at increasing the size of the intervertebral foramen (IVF) of the affected nerve root
Trial: 25420010
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and exercise program without the specific goal of increasing the size of the IVF
Trial: 25420010
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and exercise program aimed at increasing the size of the IVF of the affected nerve root
Trial: 21505984
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (conventional therapy plus continuous insulin pumping to control blood glucose at 4.4‐6.1 mmol/L)
Trial: 17584491
Drug: HIV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV RNA levels <400 copies/ml at delivery
Trial: 11471097
Drug: Ribavirin monotherapy
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin monotherapy for an additional 6 months
Trial: 8241852
Drug: Placebo soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo soft laser treatment
Trial: 31205105
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 35 mg orally twice a day for 3 months
Trial: 21741060
Drug: IGFBP-1 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGFBP-1 levels in T2DM subjects (21.7 ± 3.5 ng/mL)
Trial: 21741060
Drug: IGFBP-1 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGFBP-1 levels in NGT subjects with insulin resistance (25.5 ± 6.5 ng/mL)
Trial: 21741060
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance association with IGFBP-1
Trial: 18546895
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target concentration of 1.5 microg x ml(‐1)
Trial: 18546895
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target concentration of 2.0 microg x ml(‐1)
Trial: 12099919
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in a stroke unit (SU)
Trial: 16060935
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in a general medical ward (GMW)
Trial: 7674439
Drug: Small-movement therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-movement therapy
Trial: 2116773
Drug: Monthly intravenous
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intravenous methylprednisolone pulsing (steroid group)
Trial: 31101627
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus lenalidomide (15 mg orally daily for 18 weeks)
Trial: 31101627
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2 IV on day 1 of weeks 1‐4 and repeated during weeks 12‐15 in responding patients)
Trial: 29183037
Drug: Wiping plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wiping plus oral nutritional supplements (ONS)
Trial: 29183037
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral care (Control)
Trial: 25584004
Drug: Docetaxel 20
RxNorm normalized name: docetaxel 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 20 mg/m2 plus cisplatin 25 mg/m2 on days 1, 8, and 15, every 4 weeks
Trial: 25584004
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 on day 1, every 3 weeks
Trial: 23596781
Drug: Modified Shuyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Shuyu Pill (MSP)
Trial: 21253706
Drug: Zolpidem (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (single dose for the first seven post-operative nights)
Trial: 21253706
Drug: Placebo (gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gelatin capsule similar in appearance to zolpidem)
Trial: 19731779
Drug: Integrative relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative relaxation training (IRT) - 12 weekly group sessions
Trial: 18257345
Drug: Electrical plum-blossom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical plum-blossom needle therapy
Trial: 14724106
Drug: Parnaparin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parnaparin (0.4 ml subcutaneously every 12 h for 7 days 12 h after thrombolysis, n=96)